Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

BACKGROUND: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti–CTLA-4 treatment prolongs overall survival in patients with melanom...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:N Engl J Med
Egile Nagusiak: Snyder, Alexandra, Makarov, Vladimir, Merghoub, Taha, Yuan, Jianda, Zaretsky, Jesse M., Desrichard, Alexis, Walsh, Logan A., Postow, Michael A., Wong, Phillip, Ho, Teresa S., Hollmann, Travis J., Bruggeman, Cameron, Kannan, Kasthuri, Li, Yanyun, Elipenahli, Ceyhan, Liu, Cailian, Harbison, Christopher T., Wang, Lisu, Ribas, Antoni, Wolchok, Jedd D., Chan, Timothy A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315319/
https://ncbi.nlm.nih.gov/pubmed/25409260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1406498
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak